A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. It is hypothesized that regular treatment with TQA3526 will improve liver function in persons with Primary Biliary Cirrhosis (PBC).
Epistemonikos ID: 8a1f4be24eabea108b88fc72fbdaa0e334139eab
First added on: May 07, 2024